Aptose Biosciences Inc. (APTO) EPS Estimated At $-0.17

July 14, 2018 - By Sonya McDaniel

Analysts expect Aptose Biosciences Inc. (NASDAQ:APTO) to report $-0.17 EPS on August, 14.They anticipate $0.06 EPS change or 54.55 % from last quarter’s $-0.11 EPS. After having $-0.23 EPS previously, Aptose Biosciences Inc.’s analysts see -26.09 % EPS growth. The stock decreased 4.18% or $0.14 during the last trading session, reaching $3.21. About 513,609 shares traded or 14.83% up from the average. Aptose Biosciences Inc. (NASDAQ:APTO) has risen 252.94% since July 14, 2017 and is uptrending. It has outperformed by 240.37% the S&P500.

Aptose Biosciences Inc. (NASDAQ:APTO) Ratings Coverage

Among 2 analysts covering Aptose Biosciences (NASDAQ:APTO), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Aptose Biosciences had 6 analyst reports since March 28, 2018 according to SRatingsIntel. The firm has “Buy” rating by Roth Capital given on Monday, April 16. The rating was maintained by Roth Capital with “Buy” on Tuesday, June 5. The stock has “Buy” rating by H.C. Wainwright on Friday, June 15. H.C. Wainwright maintained it with “Buy” rating and $600 target in Monday, May 7 report. The firm earned “Buy” rating on Monday, April 16 by H.C. Wainwright. The stock of Aptose Biosciences Inc. (NASDAQ:APTO) has “Buy” rating given on Wednesday, March 28 by H.C. Wainwright.

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. The company has market cap of $109.15 million. The Company’s lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. It currently has negative earnings. The firm has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma.

More notable recent Aptose Biosciences Inc. (NASDAQ:APTO) news were published by: Benzinga.com which released: “28 Stocks Moving In Thursday’s Pre-Market Session” on July 05, 2018, also Globenewswire.com with their article: “FDA Lifts Clinical Hold so MYC Inhibitor APTO-253 Can Return to Phase 1b Trial In Patients With Hematologic Cancers” published on June 29, 2018, Investingnews.com published: “VIDEO — Life Science Update June 2018” on July 06, 2018. More interesting news about Aptose Biosciences Inc. (NASDAQ:APTO) were released by: Seekingalpha.com and their article: “Aptose Biosciences Back On Track In The Clinic” published on July 02, 2018 as well as Nasdaq.com‘s news article titled: “Aptose Biosciences to Participate at the Oppenheimer & Co. Inc. Boston Oncology Insight Summit and 1×1 Day” with publication date: July 09, 2018.

Aptose Biosciences Inc. (NASDAQ:APTO) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.